earnings
confidence high
sentiment negative
materiality 0.85
Charles River Labs Q4 revenue $994M, GAAP loss $5.62; sees 2026 non-GAAP EPS $10.70-$11.20
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
2025-FY EPS
reported -$2.91
vs consensus $2.37
▼ miss
(-223.0%)
- Q4 GAAP loss per share $(5.62) from $994.2M revenue (-0.8% YoY); non-GAAP EPS $2.39 (-10.2%).
- FY2025 revenue $4.02B (-0.9%); GAAP loss $(2.91)/share; non-GAAP EPS $10.28 (-0.4% vs $10.32).
- DSA organic revenue -3.3% in Q4; CEO cites robust DSA net bookings and cautious optimism for demand recovery.
- 2026 organic revenue guidance (1.0)% to flat; non-GAAP EPS $10.70-$11.20 implies 4-9% growth.
- Recorded $211M intangible and $165M goodwill impairments in Biologics Solutions (Manufacturing segment).